Delving into the Latest Updates on LH-1802 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LH 1802, LH-1802, LH1802

Target

KDM1A

Action

inhibitors

Mechanism

KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors), Epigenetic drug

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Myelodysplastic SyndromesRefractory acute myeloid leukemiaRelapsing acute myeloid leukemia

Inactive Indication-

Originator Organization

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization

Shanghai Institute of Materia Medica Chinese Academy of Sci

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价 LH-1802 胶囊在复发/难治性急性髓系白血病（R/R AML）或骨髓增生异常综合征（R/R MDS）患者中的安全性和耐受性，确定最大耐受剂量和剂量限制毒性；探索 LH-1802 胶囊的 II 期推荐给药剂量（RP2D）和给药方案。次要目的：评价 LH-1802 胶囊在 R/R AML 或 R/R MDS 患者中的药代动力学（PK）特征；评价 LH-1802 胶囊在 R/R AML 或 R/R MDS 患者中的药效动力学（PD）特征；评估 LH-1802 胶囊单药治疗 R/R AML 或 R/R MDS 患者的初步疗效。

[Translation]

Primary objectives: To evaluate the safety and tolerability of LH-1802 capsules in patients with relapsed/refractory acute myeloid leukemia (R/R AML) or myelodysplastic syndrome (R/R MDS), determine the maximum tolerated dose and dose-limiting toxicity; explore the Phase II recommended dose (RP2D) and dosing regimen of LH-1802 capsules. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of LH-1802 capsules in patients with R/R AML or R/R MDS; to evaluate the pharmacodynamic (PD) characteristics of LH-1802 capsules in patients with R/R AML or R/R MDS; to evaluate the preliminary efficacy of LH-1802 capsules as a single agent in the treatment of patients with R/R AML or R/R MDS.

Start Date03 Jan 2023

Sponsor / Collaborator

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

100 Clinical Results associated with LH-1802

Login to view more data

100 Translational Medicine associated with LH-1802

Login to view more data

100 Patents (Medical) associated with LH-1802

Login to view more data

100 Deals associated with LH-1802

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelodysplastic Syndromes	Phase 1	China	Jiangsu Lianhuan Pharmaceutical Co., Ltd.	03 Jan 2023
Refractory acute myeloid leukemia	Phase 1	China	Jiangsu Lianhuan Pharmaceutical Co., Ltd.	03 Jan 2023
Relapsing acute myeloid leukemia	Phase 1	China	Jiangsu Lianhuan Pharmaceutical Co., Ltd.	03 Jan 2023